Compounded vs Brand GLP-1s: What You Need to Know

The core difference is that brand GLP-1s are FDA-approved manufactured drugs, while compounded GLP-1s are custom-mixed by a pharmacy and are not FDA-approved. Brand products, semaglutide as Ozempic and Wegovy, and tirzepatide as Mounjaro and Zepbound, are made by Novo Nordisk and Eli Lilly under strict manufacturing controls, so every pen delivers a verified, consistent dose. Compounded versions are prepared by licensed compounding pharmacies that combine the active ingredient with other components, often in a vial you draw up with a syringe. Compounding is legal in specific situations, most notably during official drug shortages, and it can also involve different salt forms or added ingredients like vitamin B12. The trade-off is oversight: the FDA does not review compounded drugs for safety, effectiveness, or quality before they reach you. That does not automatically make them unsafe, but it does mean the responsibility for verifying quality shifts to the pharmacy and your prescriber. Understanding which specific molecule you are getting matters too, and our explainer on [Ozempic vs Wegovy](/blog/ozempic-vs-wegovy-same-drug-different-purpose-2026) shows how the same drug can be branded differently.

Compounded semaglutide is cheaper mainly because pharmacies buy the active ingredient in bulk and skip the branding, marketing, and patent pricing built into a name-brand pen. Where a month of brand-name Wegovy can list at over $1,300 before insurance, compounded semaglutide commonly runs $150 to $400 per month through telehealth clinics. Part of the gap is real: no billion-dollar clinical trial program or commercial supply chain to fund. But part reflects reduced oversight and the fact that compounded products do not carry the same guarantees. Cost is the number-one reason people consider compounding, and it is a legitimate concern given how expensive these medications are. Before assuming compounding is the only affordable route, it is worth exhausting savings options on brand drugs, including manufacturer savings cards and pre-tax spending accounts. Our guide on using [FSA and HSA dollars for GLP-1s](/blog/glp1-fsa-hsa-pre-tax-dollars-save-on-weight-loss-2026) covers ways to lower the brand-name cost that many people miss.

Compounded semaglutide can be safe when it comes from a reputable, state-licensed pharmacy, but the risk is that quality is not guaranteed the way it is for FDA-approved drugs. The FDA has warned about compounded GLP-1 products, citing dosing errors from patients measuring their own doses, use of unapproved salt forms like semaglutide sodium or acetate that have not been shown to be safe or effective, and products from unregulated overseas or online sellers. Legitimate compounding happens at two types of pharmacies: 503A pharmacies that fill individual prescriptions, and 503B outsourcing facilities that are FDA-registered and follow stricter manufacturing standards. Red flags include sellers who do not require a prescription, prices that seem too good to be true, missing pharmacy licensing information, and products shipped from abroad. If you use a compounded product, confirm the pharmacy is licensed in your state, ask which exact form of the drug it contains, and make sure a real prescriber is overseeing your care. The convenience of a quick online purchase is not worth an unverified vial.

Large-scale compounding of semaglutide and tirzepatide is now legally restricted because both drugs came off the FDA's official shortage list in 2025. Under federal law, compounding pharmacies can generally make copies of an approved drug when it is in shortage. Tirzepatide was declared resolved in late 2024 and semaglutide in early 2025, which removed the main legal basis for mass-producing compounded copies. The FDA set enforcement deadlines after which 503A and 503B pharmacies were expected to stop compounding these drugs as routine copies. There are narrow exceptions, such as when a prescriber documents that a patient needs a clinically different formulation (for example, a different dose or an ingredient the patient cannot get from the brand) that the standard product cannot provide. This is a fast-moving legal area, so what is permitted can change. The practical takeaway: if a clinic still offers compounded GLP-1s, ask on what legal basis, and lean on your prescriber to confirm it is appropriate for your situation rather than a workaround.

Deciding comes down to weighing cost against certainty, and doing it with a prescriber rather than alone. Start by pricing the brand drug with every discount available: insurance, manufacturer savings cards, and pre-tax accounts. If brand is affordable, its FDA approval and dose consistency make it the lower-risk choice. If cost is still a barrier, and you and your provider consider a legitimately compounded product, insist on a licensed 503A or 503B pharmacy, a clear statement of the exact drug form, and proper dosing instructions with the right syringes. Avoid any seller that skips a prescription or ships from overseas. Keep in mind that switching products or forms can change how you feel, much like switching between brand medications does; our guide on [switching from Ozempic to Mounjaro](/blog/switching-from-ozempic-to-mounjaro-when-and-how) explains why transitions deserve care. The best choice is the one that is both safe and sustainable for you, and that decision should always run through a clinician who knows your history.

Choosing between compounded and brand GLP-1s can feel overwhelming, especially with the rules changing and cost pressure pushing you toward the cheapest option. Lea can help you understand the differences, think through the questions to ask your prescriber, and map out savings routes for brand-name drugs so you can make a confident, informed choice.